ÈËÆÞÖгöÊÓƵ

Skip to main content
Michael P. Teske
( out of 354 reviews )

Michael P. Teske, MD

Languages spoken: English

Clinical Locations

John A. Moran Eye Center

Salt Lake City
801-581-2352
  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification

    American Board of Ophthalmology
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 354 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 29, 2024
    MORAN EYE CENTER

    I have been a patient of Dr. Teske's for many years. I trust him and his evaluation of ongoing treatment.

    September 28, 2024
    MORAN EYE CENTER

    Extremely knowledgeable and experienced retinal specialist. Highly recommended!

    September 27, 2024
    MORAN EYE CENTER

    I was sorry to hear thatDr Teske will retire nextJune.

    September 26, 2024
    MORAN EYE CENTER

    Just exceptional treatment. His knowledge is the best. I would recommend him to everyone for this care.

    September 26, 2024
    MORAN EYE CENTER

    Dr. Teske is a very competent, courteous and kind provider.

    September 23, 2024
    MORAN EYE CENTER

    Good nd treat people nice

    September 21, 2024
    MORAN EYE CENTER

    Dr. Teske is a wonderful doctor. I didn't ever imagine I would get the results that I did. He did a wonderful job. I can see better than I thought I ever could and better than any doctor in the area that I live ever said that they could do. He's wonderful thank you so much Dr. Teske and Dr. Kohler.

    September 21, 2024
    MORAN EYE CENTER

    Highly recommend

    September 14, 2024
    MORAN EYE CENTER

    I was mostly treated by Dr. Collins who was also courteous, respectful, a good listener. He gave clear explanations, and we jointly agreed about the best care options.

  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Primary
    Board Certification
    American Board of Ophthalmology
    National Board of Medical Examiners

    Education history

    Fellowship Retina/Vitreous - Wayne State ÈËÆÞÖгöÊÓƵ, Kresge Eye Institute Fellow
    Ophthalmology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Resident
    Internship Internal Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Intern
    Medicine - ÈËÆÞÖгöÊÓƵ of California - Los Angeles M.D.
    Undergraduate ÈËÆÞÖгöÊÓƵ of Notre Dame B.S.

    Selected Publications

    Journal Article

    1. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NK, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (08/01/2018). Effect of Oral Valproic Acid vs. Placdbo for Vision Loss in Paients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856.
    2. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856. ()
    3. Bell JE, Shulman JP, Swan RJ, Teske MP, Bernstein PS (2017). Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage. Ophthalmic Surg Lasers Imaging Retina, 48(1), 26-32. ()